CDK6 and acute myeloid leukemia: Furthermore, AC008937.3, AC018809.2, AC023090.1, CDK6-AS1, and AC073534.2 were also found to feature prominently in prognostic assessments of lung cancer (55), bladder cancer (56), hepatocellular carcinoma (57), gastric cancer (58), and acute myeloid leukemia (59), further underscoring their relevance in disease progression predictions across diverse malignancies.